Ged Giblin
Corporate Officer/Principal bei Convergence Pharmaceuticals Ltd.
Aktive Positionen von Ged Giblin
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | 06.10.2010 | - |
Karriereverlauf von Ged Giblin
Ehemalige bekannte Positionen von Ged Giblin
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| GlaxoSmithKline (Pharmaceutical Operations) | Corporate Officer/Principal | - | - |
Statistik
International
| Vereinigtes Königreich | 2 |
| Vereinigte Staaten | 2 |
Operativ
| Corporate Officer/Principal | 2 |
Sektoral
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| GlaxoSmithKline (Pharmaceutical Operations) |
- Börse
- Insiders
- Ged Giblin
- Erfahrung
